Publications

  1. Amara SV, Grbic N, Melson G, Brem CE, Almier N, Bhawan J, Alani RM, Collard
    M. Assessment of lipid and pigment content in suspicious melanocytic lesions to
    improve melanoma detection. Melanoma Res. 2023 Aug 1;33(4):283-292. doi:
    10.1097/CMR.0000000000000902. Epub 2023 Jun 5. PMID: 37276030.
  2. Gibson F, Hanly A, Fisher R, Wyant WA, Wu M, Collard M, Alani RM. Epigenetics and cutaneous neoplasms: from mechanism to therapy. Epigenomics. 2023 Feb;15(3):167-187. doi: 10.2217/epi-2023-0016. Epub 2023 Apr 5. PMID: 37020393.
  3. Gibson F, Hanly A, Grbic N, Grunberg N, Wu M, Collard M, Alani RM. Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. Clin Rev Allergy Immunol. 2022 Dec;63(3):447-471. doi: 10.1007/s12016-022-08956-8. Epub 2022 Nov 8. PMID: 36346551.
  4. Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani RM. Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma. JID Innov. 2021 Dec 13;2(2):100090. doi: 10.1016/j.xjidi.2021.100090. PMID: 35199090; PMCID: PMC8844701.
  5. Lee, H.J., Chen, Z., Collard, M., Cheng, J.G., Wu, M., Alani, R., Cheng, J. (2021). Multimodal Metabolic Imaging Identifies Pigmentation to Lipid Accumulation in Metastatic Melanoma. BME Frontiers, 2021, 9860123. doi: 10.34133/2021/9860123
  6. Kam S, Collard M, Lam J, Alani RM. Gut Microbiome Perturbations in Patients with Hidradenitis Suppurativa: A Case Series. J Invest Dermatol. 2021 Jan;141(1):225-228.e2. doi: 10.1016/j.jid.2020.04.017. Epub 2020 May 16. PMID: 32422215.
  7. Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019 Nov 11;36(5):528-544.e10. doi: 10.1016/j.ccell.2019.09.005. Epub 2019 Oct 17. PMID: 31631026.
  8. Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer Res. 2019 May 15;79(10):2649-2661. doi: 10.1158/0008-5472.CAN-18-2331. Epub 2019 Mar 25. PMID: 30910803; PMCID: PMC6522293.
  9. Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018 Apr;22(2):203-218. doi: 10.1007/s40291-018-0318-z. PMID: 29411301.
  10. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 Jan 4;9(1):53. doi: 10.1038/s41467-017-02242-4. PMID: 29302039; PMCID: PMC5754352.